Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome

被引：4
|
作者：
Yanada, Masamitsu [1 ]
Huang, Xuelin
Garcia-Manero, Guillermo
O'Brien, Susan
Ravandi, Farhad
Borthakur, Gautam
Faderl, Stefan
Issa, Jean-Pierre
Kantarjian, Hagop
Estey, Elihu
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukimia, Houston, TX 77025 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Biostatr, Houston, TX 77025 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2007年 / 138卷 / 04期
关键词：
acute myeloid leukaemia; myelodysplastic syndrome; targeted therapy; haematological improvement; survival;
D O I：
10.1111/j.1365-2141.2007.06670.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：555 / 557
页数：3
相关论文
共 50 条
  • [31] A Comparison of Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Treated On versus Off Study
    Percival, Mary-Elizabeth
    Buckley, Sarah
    Othus, Megan
    Halpern, Anna
    Huebner, Emily
    Becker, Pamela
    Shaw, Carole
    Shadman, Mazyar
    Walter, Roland
    Estey, Elihu
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S281 - S281
  • [32] Emerging treatment options for patients with high-risk myelodysplastic syndrome
    Bewersdorf, Jan Philipp
    Carraway, Hetty
    Prebet, Thomas
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [33] A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
    Mattison, Ryan
    Jumonville, Alcee
    Flynn, Patrick James
    Moreno-Aspitia, Alvaro
    Erlichman, Charles
    LaPlant, Betsy
    Juckett, Mark B.
    LEUKEMIA & LYMPHOMA, 2015, 56 (07) : 2061 - 2066
  • [34] Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study
    Ravandi, Farhad
    Assi, Rita
    Daver, Naval
    Benton, Christopher B.
    Kadia, Tapan
    Thompson, Philip A.
    Borthakur, Gautam
    Alvarado, Yesid
    Jabbour, Elias J.
    Konopleva, Marina
    Takahashi, Koichi
    Kornblau, Steven
    DiNardo, Courtney D.
    Estrov, Zeev
    Flores, Wilmer
    Basu, Sreyashi
    Allison, James
    Sharma, Padmanee
    Pierce, Sherry
    Pike, Allison
    Cortes, Jorge E.
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    LANCET HAEMATOLOGY, 2019, 6 (09): : E480 - E488
  • [35] Low-Dose Decitabine Combined with Modified Bucy Is More Effective Conditioning Regimen for High-Risk Patients with Acute Myeloid Leukaemia/Myelodysplastic Syndrome
    Tang, Xiaowen
    Cao, Jing
    Shi, Xiaojing
    Ge, Ling
    Sun, Aining
    Zhu, Xiaming
    Qiu, Huiying
    Jin, Zhengming
    Miao, Miao
    Fu, Chengcheng
    Ma, Xiao
    Chen, Feng
    Xue, Shengli
    Han, Yue
    Xue, Mengxing
    Mao, Xinliang
    Wu, Depei
    BLOOD, 2016, 128 (22)
  • [36] Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome
    Mabrey, Frances Linzee
    Gardner, Kelda M.
    Dorcy, Kathleen Shannon
    Perdue, Andrea
    Smith, Heather A.
    Davis, Alicyn M.
    Hammer, Cody
    Rizzuto, Donelle
    Jones, Sunny
    Quach, Kim
    Scott, Bart L.
    Hendrie, Paul C.
    Percival, Mary-Elizabeth M.
    Walter, Roland B.
    Appelbaum, Frederick R.
    Estey, Elihu H.
    Becker, Pamela S.
    BLOOD ADVANCES, 2020, 4 (04) : 611 - 616
  • [37] Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Chromosome 5 Abnormalities
    Mollgard, Lars
    Nilsson, Lars
    Kjeldsen, Lars
    Dybedal, Ingunn
    Dufva, Inge Hogh
    Garelius, Hege
    Norgaard, Jan Maxwell
    Linder, Olle
    Ejerblad, Elisabeth
    Astermark, Jan
    Hellstrom-Lindberg, Eva
    BLOOD, 2009, 114 (22) : 52 - 52
  • [38] Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following Myelodysplastic syndrome
    Grovdal, Michael
    Khan, Rasheed
    Aggerholm, Anni
    Antunovic, Petar
    Astermark, Jan
    Bernell, Per
    Engstroem, Lena-Varia
    Kjeldsen, Lars
    Linder, Olle
    Nilsson, Lars
    Olsson, Anna
    Wallvik, Jonas
    Tangen, Jon Magnus
    Oberg, Gunnar
    Jacobsen, Sten Eirik
    Hokland, Peter
    Porwit, Anna
    Hellstrom-Lindberg, Eva
    CLINICAL CANCER RESEARCH, 2007, 13 (23) : 7107 - 7112
  • [39] A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
    Gemici, Aliihsan
    Ozkalemkas, Fahir
    Dogu, Mehmet Hilmi
    Tekinalp, Atakan
    Alacacioglu, Inci
    Guney, Tekin
    Ince, Idris
    Geduk, Ayfer
    Cagliyan, Gulsum Akgun
    Maral, Senem
    Serin, Istemi
    Gunduz, Eren
    Karakus, Volkan
    Bekoz, Huseyin Saffet
    Eren, Rafet
    Pinar, Ibrahim Ethem
    Gunes, Ahmet Kursad
    Sargin, Fatma Deniz
    Sevindik, Omur Gokmen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (08): : E686 - E692
  • [40] Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy
    Grovdal, Michael
    Karimi, Mohsen
    Khan, Rasheed
    Aggerholm, Anni
    Antunovic, Petar
    Astermark, Jan
    Bernell, Per
    Engstrom, Lena-Maria
    Kjeldsen, Lars
    Linder, Olle
    Nilsson, Lars
    Olsson, Anna
    Holm, Mette S.
    Tangen, Jon M.
    Wallvik, Jonas
    Oberg, Gunnar
    Hokland, Peter
    Jacobsen, Sten E.
    Porwit, Anna
    Hellstrom-Lindberg, Eva
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (03) : 293 - 302
12345